NYSE:PTHN - Patheon Stock Price, Price Target & More

$34.98 0.00 (0.00 %)
(As of 04/24/2018 04:00 PM ET)
Previous Close$34.98
Today's Range$34.98 - $35.02
52-Week Range$23.72 - $35.13
Volume229,700 shs
Average Volume754,718 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A

About Patheon (NYSE:PTHN)

Patheon logoPatheon N.V. is a provider of outsourced pharmaceutical development and manufacturing services. The Company's segments include Drug Product Services (DPS), Pharmaceutical Development Services (PDS) and Drug Substance Services (DSS). The DPS segment is engaged in manufacturing and packaging for approved prescription, over-the-counter (OTC) and nutritional products. The PDS segment provides a range of formulation, production and technical services from the early stages of a product's development to regulatory approval, as well as for new formulations of approved products for lifecycle extension. The DSS segment provides small molecule active pharmaceutical ingredient (API) and outsourced manufacturing solutions for large molecule biological API from early development through commercial scale production. It provides an integrated range of API and finished drug product services to its customers, from formulation development to clinical and commercial-scale manufacturing.

Receive PTHN News and Ratings via Email

Sign-up to receive the latest news and ratings for PTHN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations


Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$1.87 billion
Price / Sales2.72
Cash FlowN/A
Price / CashN/A
Book Value($2.40) per share
Price / Book-14.58


EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A


Outstanding Shares145,140,000

How to Become a New Pot Stock Millionaire

Patheon (NYSE:PTHN) Frequently Asked Questions

What is Patheon's stock symbol?

Patheon trades on the New York Stock Exchange (NYSE) under the ticker symbol "PTHN."

How were Patheon's earnings last quarter?

Patheon NV (NYSE:PTHN) released its quarterly earnings data on Thursday, June, 8th. The company reported $0.20 earnings per share for the quarter, beating the consensus estimate of $0.19 by $0.01. The company earned $483.40 million during the quarter, compared to the consensus estimate of $466.08 million. The company's quarterly revenue was up 3.2% on a year-over-year basis. View Patheon's Earnings History.

When is Patheon's next earnings date?

Patheon is scheduled to release their next quarterly earnings announcement on Thursday, April, 26th 2018. View Earnings Estimates for Patheon.

What price target have analysts set for PTHN?

6 equities research analysts have issued 1 year target prices for Patheon's stock. Their predictions range from $35.00 to $35.00. On average, they expect Patheon's share price to reach $35.00 in the next year. View Analyst Ratings for Patheon.

Who are some of Patheon's key competitors?

Who are Patheon's key executives?

Patheon's management team includes the folowing people:
  • Paul S. Levy, Chairman of the Board
  • James C. Mullen, Chief Executive Officer, Director
  • Stuart R. Grant, Chief Financial Officer, Executive Vice President
  • Gilles A. Cottier, President - Global Pharmaceutical Development Services
  • Franco Negron, President - Drug Product Services
  • Lukas Utiger, President - Drug Substance
  • Michael J. Lehmann, Executive Vice President - Global Sales and Marketing
  • Michael E. Lytton J.D., Executive Vice President - Corporate Development and Strategy
  • Rebecca Holland New, Chief Human Resources Officer and Executive Vice President - Communications and Project Management Office
  • Harry R. Gill III, Senior Vice President - Quality and Continuous Improvement

When did Patheon IPO?

(PTHN) raised $625 million in an IPO on Thursday, July 21st 2016. The company issued 30,500,000 shares at $19.00-$22.00 per share. J.P. Morgan, Morgan Stanley, Jefferies, UBS Investment Bank, Credit Suisse, Evercore ISI and Wells Fargo Securities acted as the underwriters for the IPO and Baird, Piper Jaffray, Raymond James, William Blair, KeyBanc Capital Markets and Leerink Partners were co-managers.

Has Patheon been receiving favorable news coverage?

Headlines about PTHN stock have trended somewhat positive on Tuesday, Accern Sentiment reports. The research firm ranks the sentiment of news coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Patheon earned a media sentiment score of 0.14 on Accern's scale. They also gave news coverage about the company an impact score of 46.32 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.

How do I buy shares of Patheon?

Shares of PTHN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Patheon's stock price today?

One share of PTHN stock can currently be purchased for approximately $34.98.

How can I contact Patheon?

Patheon's mailing address is Herengracht 483, Amsterdam P7, 1017BT. The company can be reached via phone at 31-20-622-3243.

MarketBeat Community Rating for Patheon (PTHN)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  151 (Vote Outperform)
Underperform Votes:  125 (Vote Underperform)
Total Votes:  276
MarketBeat's community ratings are surveys of what our community members think about Patheon and other stocks. Vote "Outperform" if you believe PTHN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PTHN will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Patheon (NYSE:PTHN) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
7 Wall Street analysts have issued ratings and price targets for Patheon in the last 12 months. Their average twelve-month price target is $35.00, suggesting that the stock has a possible upside of 0.06%. The high price target for PTHN is $35.00 and the low price target for PTHN is $35.00. There are currently 6 hold ratings and 1 buy rating for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score:
Ratings Breakdown: 0 Sell Rating(s)
6 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
6 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
7 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
7 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $35.00$35.00$33.60$33.60
Price Target Upside: 0.06% upside0.20% upside3.81% downside3.81% downside

Patheon (NYSE:PTHN) Consensus Price Target History

Price Target History for Patheon (NYSE:PTHN)

Patheon (NYSE:PTHN) Analyst Ratings History

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/21/2017Jefferies GroupReiterated RatingHold$35.00LowView Rating Details
6/9/2017Leerink SwannDowngradeOutperform -> Market Perform$31.00 -> $35.00LowView Rating Details
6/9/2017Raymond JamesDowngradeOutperform -> Mkt PerformLowView Rating Details
6/8/2017JPMorgan ChaseDowngradeOverweight -> NeutralLowView Rating Details
5/15/2017Evercore ISIDowngradeOutperform$35.00LowView Rating Details
5/15/2017William BlairDowngradeOutperform -> Market PerformLowView Rating Details
5/15/2017Piper JaffrayDowngradeOverweight -> NeutralLowView Rating Details
3/17/2017Robert W. BairdDowngradeOutperform -> Neutral$34.00 -> $28.00LowView Rating Details
8/16/2016Credit Suisse GroupInitiated CoverageNeutral$30.00N/AView Rating Details
8/15/2016Wells FargoInitiated CoverageOutperformN/AView Rating Details
8/15/2016UBSInitiated CoverageBuy$31.00N/AView Rating Details
8/15/2016Morgan StanleyInitiated CoverageOverweight$31.00N/AView Rating Details
8/15/2016KeyCorpInitiated CoverageOverweight$33.00N/AView Rating Details
(Data available from 4/24/2016 forward)


Patheon (NYSE:PTHN) Earnings History and Estimates Chart

Earnings by Quarter for Patheon (NYSE:PTHN)

Patheon (NYSE PTHN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
6/8/20174/30/2017$0.19$0.20$466.08 million$483.40 millionViewN/AView Earnings Details
3/16/20171/31/2017$0.22$0.14$463.39 million$457.40 millionViewN/AView Earnings Details
12/20/2016Q416$0.39$0.30$496.27 million$510.20 millionViewN/AView Earnings Details
9/8/2016Q3 2016$0.07$482.00 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)


Patheon (NYSE:PTHN) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Patheon (NYSE PTHN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.14%
Institutional Ownership Percentage: 0.86%
Insider Trading History for Patheon (NYSE:PTHN)
Insider Trading History for Patheon (NYSE:PTHN)

Patheon (NYSE PTHN) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/30/2016Paul S LevyDirectorBuy10,000$29.55$295,500.00View SEC Filing  
9/28/2016Paul S LevyDirectorBuy15,000$29.64$444,600.00View SEC Filing  
9/12/2016Paul S LevyDirectorBuy37,000$28.01$1,036,370.00View SEC Filing  
7/26/2016Jll Patheon Co-Investment FundMajor ShareholderBuy815,730$19.85$16,192,240.50View SEC Filing  
7/26/2016Pamela DaleyDirectorBuy48,800$19.85$968,680.0060,705View SEC Filing  
7/21/2016Philip EykermanDirectorBuy28,000$25.00$700,000.0028,000View SEC Filing  
(Data available from 1/1/2013 forward)


Patheon (NYSE PTHN) News Headlines

Contrasting Johnson & Johnson (JNJ) and Patheon (PTHN)Contrasting Johnson & Johnson (JNJ) and Patheon (PTHN)
www.americanbankingnews.com - February 25 at 7:10 PM
Contrasting Patheon (PTHN) & Emergent Biosolutions (EBS)Contrasting Patheon (PTHN) & Emergent Biosolutions (EBS)
www.americanbankingnews.com - February 7 at 3:08 AM
Patheon NV (PTHN) Expected to Announce Earnings of $0.43 Per SharePatheon NV (PTHN) Expected to Announce Earnings of $0.43 Per Share
www.americanbankingnews.com - January 12 at 11:28 AM
Reviewing Patheon (PTHN) and Concordia International (CXRX)Reviewing Patheon (PTHN) and Concordia International (CXRX)
www.americanbankingnews.com - December 25 at 5:30 PM
Contrasting Patheon (PTHN) & Its CompetitorsContrasting Patheon (PTHN) & Its Competitors
www.americanbankingnews.com - December 20 at 9:28 PM
Head to Head Contrast: Patheon (PTHN) and Its CompetitorsHead to Head Contrast: Patheon (PTHN) and Its Competitors
www.americanbankingnews.com - December 19 at 5:22 PM
Head to Head Comparison: Patheon (PTHN) and Its PeersHead to Head Comparison: Patheon (PTHN) and Its Peers
www.americanbankingnews.com - December 16 at 1:30 AM
Analyzing Patheon (PTHN) and Its RivalsAnalyzing Patheon (PTHN) and Its Rivals
www.americanbankingnews.com - December 13 at 1:34 PM
Patheon (PTHN) vs. Its Rivals Head to Head ContrastPatheon (PTHN) vs. Its Rivals Head to Head Contrast
www.americanbankingnews.com - November 30 at 5:34 AM
Analyzing Patheon N.V. (PTHN) and Its RivalsAnalyzing Patheon N.V. (PTHN) and Its Rivals
www.americanbankingnews.com - November 24 at 11:30 AM
Financial Review: Cambrex Corporation (CBM) versus Patheon N.V. (PTHN)Financial Review: Cambrex Corporation (CBM) versus Patheon N.V. (PTHN)
www.americanbankingnews.com - November 17 at 11:44 PM

SEC Filings

Patheon (NYSE:PTHN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media


Patheon (NYSE:PTHN) Income Statement, Balance Sheet and Cash Flow Statement


Patheon (NYSE PTHN) Stock Chart for Tuesday, April, 24, 2018

Loading chart…

This page was last updated on 4/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.